# Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer

> **NCT00096304** · PHASE1 · TERMINATED · sponsor: **Medical University of South Carolina** · enrollment: 36 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** epirubicin hydrochloride

## Key facts

- **NCT ID:** NCT00096304
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-06-08
- **Primary completion:** 2006-09-06
- **Final completion:** 2007-11-30
- **Target enrollment:** 36 (ESTIMATED)
- **Why stopped:** Low accrual
- **Last updated:** 2018-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00096304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00096304, "Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00096304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*